On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
|Slideshows|September 13, 2019
Rheumatology Nurses Society Meeting Roundup: JIA, a Missed Diagnosis and More
Author(s)Whitney J. Palmer
From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month.
Advertisement
From transitioning a pediatric rheumatology patient to adult care to re-evaluating a missed diagnosis, in this slideshow, we highlight some key presentations from the annual Rheumatology Nurses Society meeting held last month.
Advertisement
Related to this article
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Advertisement
Advertisement